US 10471051
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted A61KA61K31/443A61K31/4439
Quick answer
US patent 10471051 (Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer) held by Asana BioSciences, LLC expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 38
- CPC classes
- A61K, A61K31/443, A61K31/4439, A61K31/444, A61K31/506